SiRNA silencing of the mutant keratin 12 allele in corneal limbal epithelial cells grown from patients with Meesmann's epithelial corneal dystrophy

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 5, 2014, Pages 3352-3360

  Courtney, David G ^a   Atkinson, Sarah D ^a   Allen, Edwin H A ^a   Moore, Johnny E ^a   Walsh, Colum P ^a   Pedrioli, Deena M Leslie ^b   MacEwen, Caroline J ^b   Pellegrini, Graziella ^c   Maurizi, Eleonora ^a,c   Serafini, Chiara ^c   Fantacci, Monica ^c   Liao, Haihui ^b   Irvine, Alan D ^d   McIrwin Lean, W H ^b   Tara Moore, C B ^a,b,c  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Allele discrimination; Ex vivo; Keratin 12; MECD; SiRNA

Indexed keywords

ALLELE DISCRIMINATION; EX VIVO; KERATIN 12; MECD; SIRNA;

ALLELES; CELL PROLIFERATION; CELLS, CULTURED; CORNEAL DYSTROPHY, JUVENILE EPITHELIAL OF MEESMANN; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXONS; HETEROZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-12; LIMBUS CORNEAE; MUTATION, MISSENSE; PEDIGREE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 84901610878     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-12957     Document Type: Article

References (42)

1. Lu H, Zimek A, Chen J, et al. Keratin 5 knockout mice reveal plasticity of keratin expression in the corneal epithelium. Eur J Cell Biol. 2006;85:803-811.
2. Hao J, Li SK, Kao WWY, Liu C-Y. Gene delivery to cornea. Brain Res Bull. 2010;81:256-261.
3. Meesmann A. Über eine bisher nicht beschriebene dominant vererbte Dystrophia epithelialis corneae. Ber Zusammenkunft Dtsch Ophthalmol Ges. 1938;154-158.
4. Irvine AD, Corden LD, Swensson O, et al. Mutations in corneaspecific keratin K3 or K12 genes cause Meesmann's corneal dystrophy. Nat Genet. 1997:16;184-187.
5. Szaflik JP, Ołdak M, Maksym RB, et al. Genetics of Meesmann corneal dystrophy: a novel mutation in the keratin 3 gene in an asymptomatic family suggests genotype-phenotype correlation. Mol Vis. 2008;14:1713-1718.
6. Hassan H, Thaung C, Ebenezer ND, Larkin G, Hardcastle AJ, Tuft SJ. Severe Meesmann's epithelial corneal dystrophy phenotype due to a missense mutation in the helix-initiation motif of keratin 12. Eye (Lond). 2013;27:367-373.
7. Liao H, Irvine AD, Macewen CJ, et al. Development of allelespecific therapeutic siRNA in Meesmann epithelial corneal dystrophy. PLoS One. 2011;6:e28582.
8. Allen EHA, Atkinson SD, Liao H, et al. Allele-specific siRNA silencing for the common keratin 12 founder mutation in Meesmann epithelial corneal dystrophy. Invest Ophthalmol Vis Sci. 2013;54:494-502.
9. Chiou AG, Florakis GJ, Copeland RL, Williams VA, McCormick SA, Chiesa R. Recurrent Meesmann's corneal epithelial dystrophy after penetrating keratoplasty. Cornea. 1998;17: 566-570.
10. Goldberg A, Schlötzer-Schrehardt U, Seiler T. Unilateral Meesmann's dystrophy. Int Ophthalmol. 1997;21:117-120.
11. Lewin AS, Glazer PM, Milstone LM. Gene therapy for autosomal dominant disorders of keratin. J Investig Dermatol Symp Proc. 2005;10:47-61.
12. McLean WHI, Moore CBT. Keratin disorders: from gene to therapy. Hum Mol Genet. 2011;20:R189-R197.
13. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806-811.
14. Davidson BL, McCray PB. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011;12:329-340.
15. Seyhan AA. RNAi: a potential new class of therapeutic for human genetic disease. Hum Genet. 2011;130:583-605.
16. Atkinson SD, McGilligan VE, Liao H, et al. Development of allele-specific therapeutic siRNA for keratin 5 mutations in epidermolysis bullosa simplex. J Invest Dermatol. 2011;131: 2079-2086.
17. Pedrioli DML, Fu DJ, Gonzalez-Gonzalez E, et al. Generic and personalized RNAi-based therapeutics for a dominant-negative epidermal fragility disorder. J Invest Dermatol. 2012;132; 1627-1635.
18. Smith FJD, Hickerson RP, Sayers JM, et al. Development of therapeutic siRNAs for pachyonychia congenita. J Invest Dermatol. 2008;128:50-58.
19. De Fougerolles A, Vornlocher H-P, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007;6:443-453.
20. Davis ME, Zuckerman JE, Choi CHJ, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464:1067-1070.
21. DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2010;107:8800-8805.
22. Cao T, Longley MA, Wang X, Roop DR. An inducible mouse model for epidermolysis bullosa simplex. J Cell Biol. 2001;152: 651-656.
23. Weiss JS. Corneal dystrophies: molecular genetics to therapeutic intervention-fifth ARVO/Pfizer Ophthalmics Research Institute Conference. Invest Ophthalmol Vis Sci. 2010;51: 5391-5402.
24. Corradini F, Venturi B, Pellegrini G, De Luca M. Methods for characterization/manipulation of human corneal stem cells and their applications in regenerative medicine. Methods Mol Biol. 2012;916:357-372.
25. Di Iorio E, Barbaro V, Ferrari S, Ortolani C, De Luca M, Pellegrini G. Q-FIHC: quantification of fluorescence immunohistochemistry to analyse p63 isoforms and cell cycle phases in human limbal stem cells. Microsc Res Tech. 2006;69:983-991.
26. Nieto-Miguel T, Calonge M, de la Mata A, et al. A comparison of stem cell-related gene expression in the progenitor-rich limbal epithelium and the differentiating central corneal epithelium. Mol Vis. 2011;17:2102-2017.
27. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432:173-178.
28. Miller VM, Xia H, Marrs GL, et al. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A. 2003;100: 7195-7200.
29. Smith FJ, Fisher MP, Healy E, et al. Novel keratin 16 mutations and protein expression studies in pachyonychia congenita type 1 and focal palmoplantar keratoderma. Exp Dermatol. 2000;9:170-177.
30. Prickett M, Jain M. Gene therapy in cystic fibrosis. Transl Res. 2012;161:255-264.
31. Leachman SA, Hickerson RP, Schwartz ME, et al. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther. 2010;18:442-446.
32. Munier FL, Frueh BE, Othenin-Girard P, et al. BIGH3 mutation spectrum in corneal dystrophies. Invest Ophthalmol Vis Sci. 2002;43:949-954.
33. Munier FL, Korvatska E, Djemaï A, et al. Kerato-epithelin mutations in four 5q31-linked corneal dystrophies. Nat Genet. 1997;15:247-251.
34. Boutboul S, Black GCM, Moore JE, et al. A subset of patients with epithelial basement membrane corneal dystrophy have mutations in TGFBI/BIGH3. Hum Mutat. 2006;27:553-557.
35. Korvatska E, Henry H, Mashima Y, et al. Amyloid and nonamyloid forms of 5q31-linked corneal dystrophy resulting from kerato-epithelin mutations at Arg-124 are associated with abnormal turnover of the protein. J Biol Chem. 2000;275: 11465-11469.
36. Hickerson RP, Smith FJD, Reeves RE, et al. Single-nucleotidespecific siRNA targeting in a dominant-negative skin model. J Invest Dermatol. 2008;128:594-605.
37. Courtney DG, Atkinson SD, Moore JE, et al. Development of allele-specific gene-silencing siRNAS for TGFBI arg124cys in lattice corneal dystrophy type I. Invest Ophthalmol Vis Sci. 2014;55:977-985.
38. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411; 494-498.
39. Goldbard S. Bringing primary cells to mainstream drug development and drug testing. Curr Opin Drug Discov Devel. 2006;9;110-116.
40. Polach KJ, Matar M, Rice J, et al. Delivery of siRNA to the mouse lung via a functionalized lipopolyamine. Mol Ther. 2012;20:91-100.
41. Dai Y, Zhou R, Liu L, Lu Y, Qi J, Wu W. Liposomes containing bile salts as novel ocular delivery systems for tacrolimus (FK506): in vitro characterization and improved corneal permeation. Int. J. Nanomedicine. 2013;1921.
42. Schäfer J, Höbel S, Bakowsky U, Aigner A. Liposomepolyethylenimine complexes for enhanced DNA and siRNA delivery. Biomaterials. 2010;31:6892-6900.